Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CYLD Antikörper (AA 170-338)

CYLD Reaktivität: Human WB, IHC, IP, ICC Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN1867482
  • Target Alle CYLD Antikörper anzeigen
    CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))
    Bindungsspezifität
    • 15
    • 7
    • 5
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 170-338
    Reaktivität
    • 41
    • 24
    • 18
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 35
    • 6
    • 1
    Kaninchen
    Klonalität
    • 36
    • 6
    Polyklonal
    Konjugat
    • 24
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser CYLD Antikörper ist unkonjugiert
    Applikation
    • 33
    • 15
    • 8
    • 5
    • 4
    • 4
    • 4
    • 3
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
    Verwendungszweck
    Polyclonal Antibody to Cylindromatosis (CYLD)
    Spezifität
    The antibody is a rabbit polyclonal antibody raised against CYLD. It has been selected for its ability to recognize CYLD in immunohistochemical staining and western blotting.
    Kreuzreaktivität
    Maus, Ratte
    Aufreinigung
    Antigen-specific affinity chromatography followed by Protein A affinity chromatography
    Immunogen
    Recombinant Cylindromatosis (CYLD) corresdonding to Glu170~Gly338 (Accession # Q9NQC7)
    Isotyp
    IgG
    Top Product
    Discover our top product CYLD Primärantikörper
  • Applikationshinweise

    Western blotting: 0.5-2 μg/mL

    1:470-1900 Immunohistochemistry: 5-20 μg/mL

    1:47-190 Immunocytochemistry: 5-20 μg/mL

    1:47-190 Optimal working dilutions must be determined by end user.

    Kommentare

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    Lot specific
    Buffer
    0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
    Handhabung
    Avoid repeated freeze-thaw cycles.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
    Haltbarkeit
    24 months
  • Target
    CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))
    Andere Bezeichnung
    Cylindromatosis (CYLD Produkte)
    Synonyme
    BRSS antikoerper, CDMT antikoerper, CYLD1 antikoerper, CYLDI antikoerper, EAC antikoerper, MFT antikoerper, MFT1 antikoerper, SBS antikoerper, TEM antikoerper, USPL2 antikoerper, 2010013M14Rik antikoerper, 2900009M21Rik antikoerper, C130039D01Rik antikoerper, mKIAA0849 antikoerper, cyld antikoerper, LRRGT00003 antikoerper, Rp1 antikoerper, Rp1h antikoerper, CYLD lysine 63 deubiquitinase antikoerper, cylindromatosis (turban tumor syndrome), a antikoerper, CYLD antikoerper, Cyld antikoerper, cylda antikoerper
    Hintergrund
    CDMT, CYLD1, CYLDI, EAC, USPL2, Turban Tumor Syndrome, Ubiquitin Carboxyl-Terminal Hydrolase CYLD, Ubiquitin Specific Peptidase Like 2, Deubiquitinating enzyme CYLD
    Pathways
    Apoptose, Activation of Innate immune Response
Sie sind hier:
Kundenservice